Biomark Diagnostics Stock Buy Hold or Sell Recommendation
| BMKDF Stock | USD 0.15 0.01 6.25% |
Assuming the 90 days horizon and complete risk avoidance on your part, our recommendation regarding BioMark Diagnostics is 'Strong Sell'. Macroaxis provides BioMark Diagnostics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BMKDF positions.
Check out BioMark Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as BioMark and provide practical buy, sell, or hold advice based on investors' constraints. BioMark Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
BioMark |
Execute BioMark Diagnostics Buy or Sell Advice
The BioMark recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on BioMark Diagnostics. Macroaxis does not own or have any residual interests in BioMark Diagnostics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute BioMark Diagnostics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
BioMark Diagnostics Trading Alerts and Improvement Suggestions
| BioMark Diagnostics generated a negative expected return over the last 90 days | |
| BioMark Diagnostics has high historical volatility and very poor performance | |
| BioMark Diagnostics has some characteristics of a very speculative penny stock | |
| BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 43.93 K. Net Loss for the year was (1.45 M) with profit before overhead, payroll, taxes, and interest of 43.93 K. | |
| BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
BioMark Diagnostics Returns Distribution Density
The distribution of BioMark Diagnostics' historical returns is an attempt to chart the uncertainty of BioMark Diagnostics' future price movements. The chart of the probability distribution of BioMark Diagnostics daily returns describes the distribution of returns around its average expected value. We use BioMark Diagnostics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of BioMark Diagnostics returns is essential to provide solid investment advice for BioMark Diagnostics.
| Mean Return | -0.45 | Value At Risk | -10 | Potential Upside | 0.00 | Standard Deviation | 5.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of BioMark Diagnostics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
BioMark Diagnostics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to BioMark Diagnostics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that BioMark Diagnostics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a BioMark pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | -0.81 | |
σ | Overall volatility | 5.23 | |
Ir | Information ratio | -0.11 |
BioMark Diagnostics Volatility Alert
BioMark Diagnostics exhibits very low volatility with skewness of 1.03 and kurtosis of 9.33. BioMark Diagnostics is a potential penny stock. Although BioMark Diagnostics may be in fact a good instrument to invest, many penny pink sheets are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in BioMark Diagnostics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on BioMark instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.BioMark Diagnostics Fundamentals Vs Peers
Comparing BioMark Diagnostics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze BioMark Diagnostics' direct or indirect competition across all of the common fundamentals between BioMark Diagnostics and the related equities. This way, we can detect undervalued stocks with similar characteristics as BioMark Diagnostics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of BioMark Diagnostics' fundamental indicators could also be used in its relative valuation, which is a method of valuing BioMark Diagnostics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare BioMark Diagnostics to competition |
| Fundamentals | BioMark Diagnostics | Peer Average |
| Return On Asset | -1.45 | -0.14 |
| Operating Margin | (15.72) % | (5.51) % |
| Current Valuation | 12.8 M | 16.62 B |
| Shares Outstanding | 83.29 M | 571.82 M |
| Shares Owned By Insiders | 54.77 % | 10.09 % |
| Price To Earning | (8.80) X | 28.72 X |
| Price To Sales | 105.81 X | 11.42 X |
| Revenue | 43.93 K | 9.43 B |
| Gross Profit | 43.93 K | 27.38 B |
| EBITDA | (1.22 M) | 3.9 B |
| Net Income | (1.45 M) | 570.98 M |
| Cash And Equivalents | 364.96 K | 2.7 B |
| Total Debt | 96.3 K | 5.32 B |
| Current Ratio | 0.35 X | 2.16 X |
| Book Value Per Share | (0.01) X | 1.93 K |
| Cash Flow From Operations | (1.2 M) | 971.22 M |
| Earnings Per Share | (0.01) X | 3.12 X |
| Number Of Employees | 6 | 18.84 K |
| Beta | 0.66 | -0.15 |
| Market Capitalization | 11.74 M | 19.03 B |
| Total Asset | 1.47 M | 29.47 B |
| Retained Earnings | (3.47 M) | 9.33 B |
| Working Capital | (461 K) | 1.48 B |
| Current Asset | 19 K | 9.34 B |
| Current Liabilities | 480 K | 7.9 B |
| Z Score | 69.8 | 8.72 |
| Net Asset | 1.47 M |
BioMark Diagnostics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as BioMark . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 0.15 | |||
| Day Typical Price | 0.15 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 40.69 |
About BioMark Diagnostics Buy or Sell Advice
When is the right time to buy or sell BioMark Diagnostics? Buying financial instruments such as BioMark Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having BioMark Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.